Effets secondaires indésirables des médicaments : Analyse des facteurs chimiques et biologiques

Abstract

Adverse drug reactions (ADRs) represent a major public health challenge today, due to their frequency, severity, and sometimes unpredictable nature. Understanding the underlying mechanisms of their occurrence is essential for better prevention and management. This study explores the various factors involved in ADRs, distinguishing those related to the intrinsic properties of the drug—such as affinity, selectivity, chemical structure, and the formation of reactive metabolites—from patient-specific factors, including age, sex, microbiota, physiological state, and genetic variations. In the pursuit of pharmacological safety, bioinformatics tools are playing an increasingly central role. In silico approaches, particularly QSAR models, pharmacophore modeling, and molecular docking, enable the prediction of pharmacokinetic and toxicological properties of developing molecules. These technologies make it possible to identify risks early and optimize drug candidate design from the preclinical stages. Finally, several strategies are emerging to reduce the incidence of ADRs: personalized treatments, microbiota modulation, and the integration of pharmacogenomics, which paves the way for therapies tailored to patients’ genetic profiles. These approaches converge toward a more personalized medicine model, where drug safety and efficacy rely on a global and multidisciplinary vision.